MARKET

CATX

CATX

Perspective Therapeutics Inc
AMEX
1.610
-0.650
-28.76%
After Hours: 1.649 +0.039 +2.44% 19:59 10/23 EDT
OPEN
2.400
PREV CLOSE
2.260
HIGH
2.400
LOW
1.580
VOLUME
5.61M
TURNOVER
--
52 WEEK HIGH
6.16
52 WEEK LOW
1.580
MARKET CAP
183.78M
P/E (TTM)
-1.2118
1D
5D
1M
3M
1Y
5Y
1D
Perspective Therapeutics Highlights Strong Interim NET Trial Results
TipRanks · 2d ago
Perspective Therapeutics, Inc. Announces Interim Phase 1/2a Results for [212Pb]VMT-α-NET
NASDAQ · 2d ago
Perspective Therapeutics Inc trading resumes
TipRanks · 2d ago
Perspective announces interim results from Phase 1/2a VMT-a-NET trial
TipRanks · 2d ago
Perspective Therapeutics Announces Interim Data From Its Current Phase 1/2a Clinical Study Of [212Pb]VMT-α-NET In Patients With Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors At ESMO Congress 2026
Benzinga · 2d ago
Perspective Therapeutics Inc trading halted, news pending
TipRanks · 2d ago
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities
TipRanks · 6d ago
Weekly Report: what happened at CATX last week (1012-1016)?
Weekly Report · 6d ago
More
About CATX
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

Webull offers Perspective Therapeutics Inc stock information, including AMEX: CATX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CATX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CATX stock methods without spending real money on the virtual paper trading platform.